Quarterly ResultAug 13, 2026, 07:37 AM
Indaptus Therapeutics Q2 Net Loss $1.8M; $12M Private Placement
AI Summary
Indaptus Therapeutics reported a Q2 2026 net loss of $1.8 million, a significant reduction from $5.2 million in Q2 2025, driven by an 83% decrease in R&D expenses and a 37% decrease in G&A expenses. The company strengthened its balance sheet with a $12.0 million private placement, bringing total liquidity to $11.6 million as of June 30, 2026. Concurrently, Indaptus discontinued further enrollment in its Decoy20 clinical studies and is evaluating strategic alternatives for its programs and broader operations. At its Annual Meeting, stockholders elected three directors, ratified the auditor, and approved the 2026 Equity Incentive Plan.
Key Highlights
- Q2 2026 Net Loss: $1.8 million, down from $5.2 million in Q2 2025.
- Q2 2026 R&D expenses: $0.4 million, an 83% decrease from Q2 2025.
- Q2 2026 G&A expenses: $1.4 million, a 37% decrease from Q2 2025.
- Completed $12.0 million private placement in June 2026.
- Total liquidity: $11.6 million as of June 30, 2026.
- Discontinued further enrollment in Decoy20 clinical studies.
- Stockholders elected three Class II directors at the Annual Meeting.
- Stockholders approved the 2026 Equity Incentive Plan.
Price Impact
More from INDP
More in Quarterly Result